Home > News > Hyponatraemia – Current Treatment Strategies and Perspectives for the Future
Diabetes
Read Time: 2 mins

Hyponatraemia – Current Treatment Strategies and Perspectives for the Future

Published Online: November 18th 2011 European Endocrinology, 2011;7(2):74-8 DOI: http://doi.org/10.17925/EE.2011.07.02.74
Authors: Muriel S Shannon, Christopher J Thompson
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Hyponatraemia is the commonest electrolyte abnormality found in hospital inpatients and is associated with a greatly increased morbidity and mortality. The management of hyponatraemia is predicated on correct diagnosis of the underlying cause, which relies on accurate assessment of the patient’s volume status. The syndrome of inappropriate antidiuresis (SIAD) is the most common cause of hyponatraemia and current treatments for this syndrome are poorly effective. Hypervolaemic hyponatraemia is also difficult to manage. The emergence of a new class of medications – the selective vasopressin-2 receptor antagonists or vaptans – gives clinicians an opportunity to target the underlying pathophysiology of these conditions, and represents an exciting new development in the management of hyponatraemia. In this article we review the differential diagnosis of hyponatraemia, current treatment strategies and emerging management options.

Keywords

Hyponatraemia, mortality, differential diagnosis, syndrome of inappropriate antidiuresis (SIAD), vaptans

Article:

Hyponatraemia is by far the most common electrolyte imbalance found in hospital inpatients,1 and patients with symptomatic hyponatraemia have a vastly increased mortality compared with normonatraemic controls.2 Therefore, it is essential that hyponatraemic patients receive effective and targeted therapy. However, hyponatraemia has many pathophysiological causes, each of which needs to be managed differently, making accurate diagnosis essential to enable the commencement of therapy to reduce morbidity and mortality.

Hyponatraemia is by far the most common electrolyte imbalance found in hospital inpatients,1 and patients with symptomatic hyponatraemia have a vastly increased mortality compared with normonatraemic controls.2 Therefore, it is essential that hyponatraemic patients receive effective and targeted therapy. However, hyponatraemia has many pathophysiological causes, each of which needs to be managed differently, making accurate diagnosis essential to enable the commencement of therapy to reduce morbidity and mortality. The recent emergence of the vaptan class of aquaretic agents is an exciting new development in the management of euvolaemic hyponatraemia, but hyponatraemia remains poorly managed. In this article, we review the diagnosis of hyponatraemia, current management strategies and emerging therapeutic options.

Prevalence and Effects of Hyponatraemia

Hyponatraemia is by far the most common electrolyte abnormality in hospital inpatients, and is also common in healthy patients in the community. The prevalence of mild hyponatraemia (<135 mmol/l) was quoted as 4 % in a recent Belgian study,3 which looked at a healthy, elderly population. The incidence of new hyponatraemia in hospitalised patients is far higher – a recent study showed that 8 % of patients admitted with pneumonia developed hyponatraemia during the course of hospital admission,4 and our own data shows that 56 % of patients admitted with subarachnoid haemorrhage develop hyponatraemia.5 Other neurosurgical patients also have high rates of hyponatraemia, with between 10 and 20 % of patients with intracranial tumours, haematomas undergoing pituitary surgery developing hyponatraemia.6

These high prevalence rates are important due to almost universal findings of higher morbidity and mortality in patients with low plasma sodium concentrations. Gill’s study of hospitalised patients with plasma sodium concentration <125 mmol/l showed an overall mortality of 28 %, significantly higher than in eunatraemic controls (9 %).7 Mortality in this study increased exponentially as plasma sodium fell. This excess mortality has also been shown to persist for months after discharge from hospital,8 although at least some of this excess mortality was attributed to the illnesses which precipitated hyponatraemia, such as cardiac failure, liver disease, and small cell carcinoma of the lung. However, hyponatraemia itself has recently been shown to be implicated in the mortality suffered by these patients, with higher mortality rates in hyponatraemic patients who did not receive specific treatment for hyponatraemia compared with those who did (37 versus 13 %).9 It has also been shown that of commonly measured clinical and biochemical parameters in acute hospital admissions, plasma sodium concentration was most strongly associated with in-hospital mortality, with an odds ratio of 4.4.10 Hyponatraemia has also been associated with increased duration of hospital stay with resultant increased hospital costs.5,7
The adverse outcomes outlined above that are associated with hyponatraemia are not confined to patients with plasma sodium <125 mmol/l. Patients with mild hyponatraemia in the community,3 with pneumonia,4 and in intensive care11 have all been shown to have excess mortality compared with patients with normal plasma sodium concentrations. The largest study to date on this topic showed that even mild hyponatraemia in hospital inpatients (which occurred in14.5 % of those studied) increased mortality at one year and five years.12 A recent analysis of the American National Health and Nutrition Examination Survey III (NHANES III) database has revealed that mild (mean 133 mmol/l) chronic hyponatraemia is associated with osteoporosis at the femoral neck.13 These recent data have challenged the traditional view of mild hyponatraemia as an asymptomatic condition and renewed interest in the treatment of hyponatraemia of all levels of severity.

Differential Diagnosis of Hyponatraemia

The first step in the treatment of hyponatraemia is correct diagnosis of the underlying aetiology. There are a number of classifications of the pathogenesis of hyponatraemia. Some authorities use a classification based on whether hyponatraemia is dilutional, depletional, or redistributional in nature.14 In routine clinical practice, we classify hyponatraemia based on clinical and biochemical estimation of extracellular volume status. This divides hyponatraemia into hypovolaemic, euvolaemic, and hypervolaemic aetiologies (see Table 1). Although the clinical features of the three categories are quite distinct, in practice it can be difficult to distinguish mild hypovolaemia from euvolaemia. The causes of hyponatraemia are numerous and diverse, and so accurate diagnosis is essential to enable correct management. Hypovolaemic hyponatraemia can be difficult to diagnose as serum urea may be low in hypovolaemic elderly patients and urinary sodium may be low in SIAD due to anorexia. In these cases, an isotonic saline infusion can be helpful.15

Euvolaemic hyponatraemia, usually caused by the syndrome of inappropriate antidiuresis (SIAD) is the commonest cause of hyponatraemia in hospitalised patients. However, it is important that SIAD is not diagnosed erroneously as a number of other pathologies can result in euvolaemic hyponatraemia, for which the management is markedly different. For example, hyponatraemia may occur as a direct result of surgical procedures – bladder irrigation during transurethral resection of the prostate gland can lead to direct absorption of water from the bladder, producing euvolaemic dilutional hyponatraemia,16,17 and inappropriate fluid replacement may also cause dilutional hyponatraemia.18 Adrenocorticotrophic hormone (ACTH) deficiency, which leads to cortisol but not aldosterone deficiency, can cause euvolaemic hyponatraemia with a biochemical picture identical to SIAD. This is due to the fact that plasma cortisol is necessary to excrete free water.19 This distinction is especially important to make in patients with neurosurgical conditions, who commonly develop hyponatraemia.6 Over 50 % of patients with acute subarachnoid haemorrhage develop hyponatraemia, most of which has been attributed to SIAD.7 Some of the hyponatraemia attributed in the immediate post-haemorrhage period to SIAD may actually represent acute ACTH deficiency. This is as yet unproven; however, 16 % of patients with acute traumatic brain injury develop ACTH deficiency20 and some of these patients develop very severe hyponatraemia.21

Current Treatment of Hyponatraemia

As outlined above, the management of hyponatraemia is critically dependent on an accurate estimation of the patient’s extracellular volume status, and the accurate diagnosis of the underlying cause (see Table 1). Incorrrect diagnosis of the patient’s volume status could lead to harmful or even fatal mistakes in treatment.

In hypovolaemic hyponatraemia, the aim is to correct plasma sodium and simultaneously restore intravascular volume. Most cases will respond to the intravenous infusion of 0.9 % isotonic saline. Diuretic therapy should be discontinued, and an underlying cause sought and treated. Co-existent Addison’s disease is suggested by history, examination, and the presence of hyperkalaemia. Although the biochemical abnormalities of Addison’s disease will respond to high-dose corticosteroids, patients usually need intravenous saline to expand blood volume and replace body sodium; intravenous dextrose may also be needed if the patient is hypoglycaemic.

Euvolaemic hyponatraemia is usually, but not always, due to syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH), and therefore the most important element in diagnosis is the recognition of other causes, especially glucocorticoid deficiency. Glucocorticoid therapy has been shown to suppress arginine vasopressin (AVP) secretion,22 which allows free water excretion and the normalisation of plasma sodium concentrations in patients with ACTH deficiency.23

Fluid restriction is regarded as the first-line treatment for hyponatraemia due to SIAD (in the majority of cases apart from patients with severe symptomatic hyponatraemia). It is well established and safe. Fluid restriction of 800–1,200 ml per day is generally advised, according to severity of hyponatraemia. However, strict fluid restriction is extremely difficult to maintain, especially in the community, as thirst in SIAD is inappropriately normal due to a downward resetting of the osmotic thirst threshold.24 Furthermore, intravenous antibiotic or cytotoxic therapy alone can push patients over their allotted fluid restriction. As a result, fluid restriction is often insufficient to reverse hyponatraemia and is rarely quick enough to manage symptomatic hyponatraemia.

Demeclocycline is a tetracycline derivative that causes nephrogenic diabetes insipidus in about 60 % of patients for whom it is prescribed, and so is sometimes used to treat SIAD. Its mode of action is unknown and unpredictable; it is often ineffective. The onset of action is also unpredictable, usually occurring after two to five days, but occasionally taking longer. Conversely, some patients may develop profound polyuria and even hypernatraemia. Reversible and even permanent nephrotoxicity can arise, particularly in patients with cirrhosis.25 It may also cause photosensitive skin rash. Lithium therapy also causes nephrogenic diabetes insipidus in 30 % of patients,26 by downregulation of vasopressin-stimulated aquaporin-2 expression,27 but similar to demeclocycline its efficacy is unpredictable as not all patients develop nephrogenic diabetes insipidus, and it also has multiple side effects. These include permanent nephrogenic diabetes insipidus,28 interstitial nephritis,29 end-stage kidney disease,30 hypothyroidism and hyperparathyroidism.
Urea is used in some centres in the management of SIAD; however, it is unavailable in many countries and the unpleasant taste has limited its use. Long-term treatment of hyponatraemia with urea is effective31 and the does not appear to lead to the development of severe complications such as myelinolysis.32,33 Frusemide may also be effective in the rapid correction of hyponatraemia in SIADH,34 but as it is a natriuretic agent, it may actually worsen hyponatraemia.

It is often difficult to clinically differentiate between hypovolaemia and euvolaemia. In these patients, intravenous saline is a safer first-line treatment than fluid restriction (as fluid restriction may exacerbate hypovolaemic hyponatraemia). Plasma sodium concentration will rise in some patients with SIADH who are treated with isotonic saline, particularly if urine osmolality is <530 mOsm/kg.28 However, this is only effective in a minority of patients.

In hypervolemic hyponatraemia, therapy is again aimed at the underlying cause. In congestive cardiac failure and cirrhosis, the mainstays of therapy are a combination of diuretics and fluid restriction to normalize total body water, in combination with inhibition of the renin angiotensin axis using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and/or spironolactone. Much research has focused on the development of aquaretic agents to correct total body water and hence correct serum sodium in both euvolaemic and hypervolemic hyponatraemia; these will be discussed in more detail below.

Treatment of severe hyponatraemia is of particular importance as untreated severe hyponatraemia, especially when associated with evidence of cerebral irritation such as seizures, is potentially fatal and recovery may occur with permanent brain damage. However, treatment is also hazardous with the risk for developing cerebral demyelination, characterised by spastic quadriparesis, cranial nerve palsies, pseudobulbar palsy, with behavioural changes, altered cognition and ‘locked in syndrome’. This usually affects the pontine area (known as central pontine myelinolysis [CPM]), but 10 % of cases involve the cerebellum, thalamus, midbrain, and lateral geniculate body35 and is caused by over-rapid correction of hyponatraemia, usually when the low plasma sodium concentration is long standing. The risk is much higher in patients with chronic alcohol abuse, and in young women. The main figure that is not to be exceeded in chronic hyponatraemia is a sodium correction rate of 0.5 mmol/l/hour.36 If plasma sodium is corrected more rapidly than this, there is a rapid restoration of intracellular sodium and potassium, but extracellular organic solutes may take five to seven days to normalise. This leads to a hypertonic extracellular compartment that causes extracellular movement of water to the myelin sheath outside the nerve cell. This leads to intramyelinic oedema, osmotic endothelial injury, and local release of myelinotoxic factors, precipitating oligodendrocyte failure and death.37

There is no consensus in terms of how fast hyponatraemia should be corrected in acute severe hyponatraemia. The risk for CPM is less in acute hyponatraemia, and treatment needs to be rapid to avoid cerebral oedema and death. However, CPM is still a major concern if correction is over-rapid. An expert panel published guidelines for the rate of intravenous infusion of hypertonic saline38 and the Adrogue – Madias formula has also been used.39 However, the Adrogue – Madias equation can lead to underestimation of the rate of rise of plasma sodium, and the patient must be carefully monitored with frequent measurement of plasma sodium concentration in order to prevent over-correction.40 Our unit would start therapy with a fixed low-dose infusion rate and adjust the rate of infusion on the basis of two-hourly plasma sodium concentrations, in order to maintain a rate of rise of plasma sodium concentration of <0.5 mmol/l/hour, or 12 mmol/l over 24 hours. The maximum rate of rise of plasma sodium should be <8 mmol/l/24 hours in patient groups at greater risk for CPM, such as alcoholics, malnourished individuals, and slim young women.

Future Treatment Strategies for Hyponatraemia

As outlined above, SIAD is one of the most common causes of hyponatraemia; it is also the cause for which current available treatments are unsatisfactory. Current treatments for hypervolemic hyponatraemia are also poor, with the development of hyponatraemia being recognised as a poor prognostic indicator in cardiac failure41 and cirrhosis.42 It has been recognised for decades that plasma vasopressin concentrations are elevated in almost every case of SIAD.43 It is also known that the fall in mean arterial pressure in hypervolemic hyponatraemia due to cardiac failure and cirrhosis stimulates baroregulated vasopressin secretion, baroregulated activation of the rennin–angiotensin–aldosterone axis, and increased sympathetic tone,44 with consequent water retention and dilutional hyponatraemia. Specific antagonists to the vasopressin–2 receptor have now been developed. This new class of drugs is termed the vaptan class and is the first treatment for SIAD and hypervolemic hyponatraemia, which targets the underlying physiology. The vaptans can be described as aquaretic rather than diuretic agents as they specifically prevent the reabsorption of water from the renal tubules.

Vasopressin exerts its antidiuretic effect by binding to the V2 receptors, which are situated in the basolateral surface of the cells of the collecting duct of the kidney. The binding of vasopressin to its receptor initiates an intracellular cascade resulting in an increase of intracellular cyclic adenosine monophosphate (cAMP). This causes protein synthesis, which leads to the production of messenger RNA (mRNA) for aquaporin-2, and insertion of pre-formed aquaporin into the apical membrane of the cell, allowing passage of free water across the cell. This free water is then reabsorbed into the renal vasculature45 and from there to the systemic circulation. The vaptans competitively bind to the V2 receptors, preventing the generation of aquaporin-2, thus causing a solute-free aquaresis.

The use of the vaptans as a treatment for SIAD began in 2009 when the European Medicines Agency (EMA) granted a licence for the use of tolvaptan specifically for the treatment of adult patients with hyponatraemia secondary to SIAD. In the US, this medication has also been licensed for the treatment of hypervolemic hyponatraemia. Tolvaptan is an oral V2 receptor antagonist that has been shown in healthy individuals to have a greater aquaresis than either frusemide or hydrochlorothiazide, without having a significant natriuresis or kaliuresis.46 The two pivotal trials of tolvaptan were Study of ascending levels of tolvaptan in hyponatraemia 1 (SALT-1) (conducted in the US) and SALT-2 (conducted in the US and Europe) trials.47 These studies included individuals with hyponatraemia due to cardiac failure, liver failure, and SIAD. Both studies were designed as randomised, placebo-controlled trials of tolvaptan versus placebo; patients were not required to maintain fluid restriction. The tolvaptan dose was adjusted from 15–60 mg daily according to clinical need, and continued for 30 days, with patient monitoring continued for seven days after discontinuation of tolvaptan. Mean baseline serum sodium was similar in both groups at 128 mmol/l. Serum sodium underwent a predictable rise to a mean of 136 mmol/l in the tolvaptan group by the end of the study and did not change significantly in the placebo group. The greatest rise in serum sodium concentration was in those patients with the lowest baseline plasma sodium concentration.

The main side effects encountered were thirst and dry mouth due to the aquaretic effect of tolvaptan. A small number of patients had a serum sodium concentration rise of more than 0.5 mmol/l/hour; none suffered any neurological sequela. An open-label extension of the SALT-1 and -2 studies of almost two years duration showed that the serum sodium normalisation was sustained and only five of 111 patients experienced an over-rapid correction of serum sodium levels, with one of 111 developing hypernatraemia.48 None of these patients developed any neurological complications. The SALT studies also examined the Short Form 12 (SF-12) Mental Component Scores before and after therapy; the mean scores significantly improved in the hyponatraemic cohort, indicating that treatment was symptomatically beneficial.
The mean baseline plasma sodium concentration in SALT-1 and -2 was 128 mmol/l, thus it is not possible to comment on the effect of tolvaptan in those patients with severe hyponatraemia who are at most risk for CPM. This is a particularly important consideration, given the observation that the greatest rise in plasma sodium occurred in those patients with the lowest baseline concentrations. Therefore, there is not yet enough evidence to show that tolvaptan can induce a predictable and controllable rise in plasma sodium concentration in those patients who have severe, acute, symptomatic hyponatraemia and who are currently managed with hypertonic saline. The best data looking at a more severely hyponatraemic cohort is taken from a study on the management of hyponatraemia with either intravenous conivaptan (a compound not yet available in Europe) or placebo.49 Subgroup analysis of those subjects with SIAD, some of whom had plasma sodium concentrations as low as 115 mmol/l, showed that conivaptan therapy led to a safe, effective, and predictable normalisation of plasma sodium concentrations. However, patients requiring emergency treatment with hypertonic saline were excluded.

The most likely role for the vaptans in the immediate future is in the treatment of mild to moderate hyponatraemia due to SIAD. None are yet licensed for the management of hypervolemic hyponatraemia in Europe, and they are not yet proven in the management of acute, symptomatic, severe hyponatraemia. The vaptans may replace water restriction as first-line treatment for SIAD, given the frequent failure of fluid restriction and the fact that tolvaptan is effective without the need for fluid restriction.47 However, the high cost of the vaptans compared with fluid restriction may limit their usage. This potential stumbling block may be overcome by the fact that a number of recent studies have shown that hyponatraemia increases duration of hospital stay4,5 and intensive care stay,4,11 regardless of the cause.

Data from the Integrated Health Care Information Services National Managed Care Benchmark Database in the US calculated that hyponatraemia was a predictor on cumulative medical costs at six months (41 % increase) and 12 months (46 %) after discharge from hospital.50 Therefore, there is a growing acceptance that hyponatraemia significantly increases healthcare costs; if future studies can show that vaptan therapy reduces this cost by safely and effectively correcting hyponatraemia then their current high costs may become more acceptable.

The other potential problem with widespread use of the vaptans is that of inappropriate prescription; specifically their incorrect use in hypovolaemic hyponatraemia that would worsen the clinical situation. It is not always easy to differentiate between euvolaemia and mild hypovolaemia, if the diagnosis is uncertain a careful isotonic saline challenge may be the safest first step. Patients with hypovolaemic hyponatraemia are likely to respond well whereas patients with SIAD are likely to have a modest response, if any. Thus, despite the availability of an exciting new class of therapeutic agents, clinical acumen remains essential to the accurate diagnosis and management of hyponatraemia.51

Conclusion

Hyponatraemia is the most commonly encountered electrolyte abnormality and is associated with significant morbidity and mortality. Effective treatment is therefore necessary for all levels of hyponatraemia. Correct evaluation of the patient’s volume status is essential to accurately diagnose the underlying cause of hyponatraemia. SIAD is the most common pathophysiological process underlying hyponatraemia and current treatment modalities for this syndrome are poorly effective. The development of the vaspressin-2 receptor antagonist class of medications gives clinicians the ability to target the underlying pathophysiology of SIAD and hypervolemic hyponatraemia. However, use of these agents may be restricted by their cost. Furthermore, more data is required in terms of the use of these agents in acute severe symptomatic hyponatraemia.

Article Information:
Disclosure

The authors have no conflicts of interest to declare

Correspondence

Christopher J Thompson, Academic Department of Endocrinology, Beaumont Hospital, Dublin 9, Ireland. E: christhompson@beaumont.ie

Received

2011-02-28T00:00:00

References

  1. Baran D, Hutchinson TA, The outcome of hyponatraemia in a general hospital population, Clin Nephrol, 1984;22:72–6.
  2. Anderson RJ, Hospital-associated hyponatraemia, Kidney Int, 1986;29:1237–47.
  3. Sajadieh A, Binici Z, Mouridsen MR, et al., Mild hyponatraemia carries a poor prognosis in community subjects, Am J Med, 2009;122:679–86.
  4. Zilberberg MD, Exuzides A, Spalding J, et al., Hyponatraemia and hospital outcomes among patients with pneumonia: a retrospective cohort study, BMC Pulm Med, 2008;8:16.
  5. Sherlock M, O'Sullivan E, Agha A, et al., The incidence and pathophysiology of hyponatraemia after subarachnoid hemorrhage, Clin Endocrinol (Oxf), 2006;64:250–4.
  6. Sherlock M, O'Sullivan E, Agha A, et al., Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients, Postgrad Med J, 2009;85:171–5.
  7. Gill G, Huda B, Boyd A, et al., Characteristics and mortality of severe hyponatraemia–a hospital-based study, Clin Endocrinol (Oxf), 2006;65:246–9.
  8. Clayton JA, Le Jeune IR, Hall IP, Severe hyponatraemia in medical in-patients: etiology, assessment and outcome, QJM, 2006;99:505–11.
  9. Hoorn EJ, Lindemans J, Zietse R, Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management, Nephrol Dial Transplant, 2006;21:70–6.
  10. Asadollahi K, Hastings IM, Beeching NJ, Gill GV, Laboratory risk factors for hospital mortality in acutely admitted patients, QJM, 2007;100:501–7.
  11. Stelfox HT, Ahmed SB, Khandwala F, et al., The epidemiology of intensive care unit-acquired hyponatraemia and hypernatremia in medical-surgical intensive care units, Crit Care, 2008;12:R162.
  12. Waikar SS, Mount DB, Curhan GC, Mortality after hospitalization with mild, moderate, and severe hyponatraemia, Am J Med, 2009;122:857–65.
  13. Verbalis JG, Barsony J, Sugimura Y, et al., Hyponatraemiainduced Osteoporosis, J Bone Miner Res, 2010;25(3):554–63.
  14. Gill G, Leese G, Hyponatraemia: biochemical and clinical perspectives, Postgrad Med J, 1998;74:516–23.
  15. 15. Musch W, Decaux G, Treating the syndrome of inappropriate ADH secretion with isotonic saline, QJM, 1998;91:749–53.
  16. Hahn RG, Fluid absorption in endoscopic surgery, Br J Anesth, 2006;96:8–20.
  17. Osborn DE, Rao PN, Greene MJ, Barnard RJ, Fluid absorption during transurethral resection, Br Med J, 1980;281:1549–50.
  18. Rosner MH, Exercise-associated hyponatraemia, Phys Sportsmed, 2008;36:55–61.
  19. Green HH, Harrington AR, Valtin H, On the role of antidiuretic hormone in the inhibition of acute water diuresis in adrenal insufficiency and the effects of gluco- and mineralocorticoids in reversing the inhibition, J Clin Invest, 1970;49:1724–36.
  20. Agha A, Rogers B, Mylotte D, et al., Neuroendocrine dysfunction in the acute phase of traumatic brain injury, Clin Endocrinol (Oxf), 2004;60:584–91.
  21. Agha A, Sherlock M, Thompson CJ, Post-traumatic hyponatraemia due to acute hypopituitarism, QJM, 2005;98:463–4.
  22. Erkut ZA, Pool C, Swaab DF, Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons, J Clin Endocrinol Metab, 1998;83:2066–73.
  23. Oelkers W, Hyponatraemia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism, N Engl J Med, 1989;321:492–6.
  24. Smith D, Moore K, Tormey W, et al., Downward resetting of the osmotic threshold for thirst in patients with SIADH, Am J Physiol Endocrinol Metab, 2004;287:E1019–23.
  25. Carrilho F, Bosch J, Arroyo V, et al., Renal failure associated with demeclocycline in cirrhosis, Ann Intern Med, 1977;87:195–7.
  26. Baylis PH, Heath DA, Water disturbances in patients treated with oral lithium carbonate, Ann Intern Med, 1978;88:607–9.
  27. Nielsen J, Hoffert JD, Knepper MA, et al., Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation, Proc Natl Acad Sci U S A, 2008;105:3634–9.
  28. Thompson CJ, Freeman J, Record CO, Baylis PH, Hypernatremia due to a reset osmostat for vasopressin release and thirst, complicated by nephrogenic diabetes insipidus, Postgrad Med J, 1987;63:979–82.
  29. Walker RG, Escott M, Birchall I, et al., Chronic progressive renal lesions induced by lithium, Kidney Int, 1986;29:875–81.
  30. Grunfeld JP, Rossier BC, Lithium nephrotoxicity revisited, Nat Rev Nephrol, 2009;5:270–6.
  31. Decaux G, Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide, Am J Med, 2001;110:582–4.
  32. Soupart A, Schroeder B, Decaux G, Treatment of hyponatraemia by urea decreases risks of brain complications in rats. Brain osmolyte contents analysis, Nephrol Dial Transplant, 2007;22:1856–63.
  33. Van Reeth O, Decaux G, Rapid correction of hyponatraemia with urea may protect against brain damage in rats, Clin Sci (Lond), 1989;77:351–5.
  34. Hantman D, Rossier B, Zohlman R, Schrier R, Rapid correction of hyponatraemia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline, Ann Intern Med, 1973;78:870–5.
  35. Wright DG, Laureno R, Victor M, Pontine and extrapontine myelinolysis, Brain, 1979;102:361–85.
  36. Cluitmans FH, Meinders E, Management of severe hyponatraemia: rapid or slow correction?, Am J Med, 1990;88:161–6.
  37. Mickel HS, Oliver CN, Starke-Reed PE, Protein oxidation and myelinolysis occur in brain following rapid correction of hyponatraemia, Biochem Biophys Res Commun, 1990;172:92–7.
  38. Verbalis JG, Goldsmith SR, Greenberg A, et al., Hyponatraemia treatment guidelines 2007: expert panel recommendations, Am J Med, 2007;120:S1–21.
  39. Adrogue HJ, Madias NE, Hyponatraemia, N Engl J Med, 2000;342:1581–9.
  40. Mohmand HK, Issa D, Ahmad Z, et al., Hypertonic saline for hyponatraemia: risk for inadvertent overcorrection, Clin J Am Soc Nephrol, 2007;2:1110–7.
  41. Chatterjee K, Hyponatraemia in heart failure, J Intensive Care Med, 2009;24:347–51.
  42. Jenq CC, Tsai MH, Tian YC, et al., Serum sodium predicts prognosis in critically ill cirrhotic patients, J Clin Gastroenterol, 2010;44:220–6.
  43. Robertson GL, Aycinena P, Zerbe RL, Neurogenic disorders of osmoregulation, Am J Med, 1982;72:339–53.
  44. Schrier RW, Fassett RG, Pathogenesis of sodium and water retention in cardiac failure, Ren Fail, 1998;20:773–81.
  45. Lien YH, Shapiro JI, Hyponatraemia: clinical diagnosis and management, Am J Med, 2007;120:653–8.
  46. Shoaf SE, Bramer SL, Bricmont P, Zimmer CA, Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non–peptide AVP antagonist, and furosemide or hydrochlorothiazide, J Cardiovasc Pharmacol, 2007;50:213–22.
  47. Schrier RW, Gross P, Gheorghiade M, et al., Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatraemia, N Engl J Med, 2006;355:2099–112.
  48. Berl T, Quittnat-Pelletier F, Verbalis JG, et al., Oral tolvaptan is safe and effective in chronic hyponatraemia, J Am Soc Nephrol, 2010;21:705–12.
  49. Verbalis JG, Zeltser D, Smith N, et al., Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolemic hyponatraemia: subgroup analysis of a randomized, controlled study, Clin Endocrinol (Oxf), 2008;69:159–68.
  50. Shea AM, Hammill BG, Curtis LH, et al., Medical costs of abnormal serum sodium levels, J Am Soc Nephrol, 2008;19:764–70.
  51. Fenske W, Maier SK, Blechschmidt A, et al., Utility and limitations of the traditional diagnostic approach to hyponatraemia: a diagnostic study, Am J Med, 2010;123:652–7.

Further Resources

Share this Article
Related Content In Diabetes
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72